ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

FDA Approval of E7777 (Denileukin Diftitox) for R/R CTCL - Summary o…

Yale Cancer Center

F. Foss

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

FL: How Do I Deal With Relapse?

SOHO Brazil 2024

B. Kahl

Summary of Bispecific Antibodies for Follicular Lymphoma

UChicago Medicine

D. Russler-Germain

Overview of CNS Cancers

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

V. Venur

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

FL Updates: Is There a Standard 1L Treatment?

SOHO Brazil 2024

B. Kahl

FDA Approval of Epcoritamab in R/R FL: What You Need to Know

Yasmin Karimi

Standards of Care and Future Directions in FL

Martin Dreyling

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

Tazemetostat in Older Frail Adults With Follicular Lymphoma

Erin Mulvey

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

Tazemetostat in R/R FL: Impact of EZH2 Mutational Status on PFS

Bruce D. Cheson

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema